• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

MPS IIIA - Articles and news items

Abeona Therapeutics completes cohort in Sanfilippo syndrome trial

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

The first-in-man clinical trial utilises a single injection of AAV gene therapy for patients with MPS IIIA (Sanfilippo syndrome type A), a rare autosomal recessive disease that causes neurocognitive decline, speech loss, loss of mobility, and premature death…

 

Webinar: SIFT-MS: A New Tool for Impurity Profiling in Pharmaceutical ProductsLEARN MORE
+ +